Compare Sanofi SA (SNY) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Growth Index Fund ETF — how do they compare? Sanofi SA trades at $43.53 (market cap $104.30B), while Vanguard Growth Index Fund ETF trades at $88.87. The key difference: Sanofi SA pays a 5.55% dividend while Vanguard Growth Index Fund ETF pays none, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | VUG | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $52.34 | $90.29 |
52-Week Low | $41.33 | $70.00 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Vanguard Growth ETF (VUG) trades at $89.01, down 0.19% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights strong institutional buying, with multiple firms increasing stakes by over 500% in Q2 2026 (Defense World, August 2026). The ETF focuses on large-cap growth stocks, benefiting from exposure to tech leaders like Microsoft.
The outlook remains positive given institutional accumulation and growth stock momentum, though high RSI levels suggest near-term consolidation risk. Key risks include market volatility and sector concentration, but long-term growth exposure aligns with bullish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
